Esperite N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 mrt 2015 - 07:27
Statutaire naam
Esperite N.V.
Titel
ESPERITE (ESP) acquires InKaryo, US start-up specialised in Bioinformatics for genetic diagnostics and molecular cytogenetic tests
Bericht
ESPERITE's strengthens its diagnostic tests to top the market with eKaryotype, electronic whole-genome Karyotype test.
Esperite welcomes Xitong li, Ph.D., ex-Verinata Illumina Director of Bioinformatics
Geneva, Switzerland - 19 March 2015
ESPERITE announces the acquisition of InKaryo, the US-based company from Silicon Valley specialized in cytogenetic analysis through next generation sequencing (NGS). ESPERITE incorporates Xitong Li, Ph.D., -former Director of Bioinformatics at Verinata Illumina- to its expert team to advance molecular diagnostics and translate breakthrough technology into high quality wider scope and affordable genetic tests to top the predictive and personalized medicine sector. This acquisition avails ESPERITE the most advanced bioinformatics analytical processing of NGS data for the detection and quantification of chromosomal numerical and structural abnormalities, improving and expanding the performance and resolution of the entire present and future genetic tests portfolio. Pursuant to the transaction, ESP will acquire the Inkaryo shares at a purchase price of USD260,000, and assume its obligations under its 2-year 6% USD 280,000 convertible bond due May 2015. Except for a small USD40,000 cash payment on completion, ESP is entitled to pay the purchase price in shares. If it elects to do so, the Sellers collectively will receive 73,530 new ESP shares. ESP is entitled to convert the convertible bond in ESP shares at a conversion price of EUR2.99.
ESPERITE will top the genetic tests market by analysing the entire genome for all chromosomal and sub- chromosomal abnormalities applicable to pre-natal genetic analyses, identification of causes of genetic disorders and high resolution tumor characterization.
Gerelateerde downloads
Datum laatste update: 19 december 2025